🇺🇸 FDA
Pipeline program

91-day Levonorgestrel Oral Contraceptive

PSE-HSP-203

Phase 2 small_molecule completed

Quick answer

91-day Levonorgestrel Oral Contraceptive for Hemostasis is a Phase 2 program (small_molecule) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TEVA PHARMACEUTICAL INDUSTRIES LTD
Indication
Hemostasis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials